Daewoong Pharmaceutical has announced the publication of research confirming the safety and effectiveness of its diabetes drug, Envlo, in animals. The study, titled "Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot study," was published in the peer-reviewed journal Veterinary Medicine and Science. The research involved testing Envlo on diabetic dogs for a year, demonstrating an 18 percent decrease in fructosamine levels and no significant side effects. The company highlighted that Envlo, an SGLT-2 inhibitor, is the 36th new drug developed in South Korea and has shown efficacy in reducing blood sugar levels in humans. Researcher Lim Soo emphasized the potential for Envlo to become a new treatment option in the veterinary drug market, particularly as there are currently no oral medications for diabetes in pets. Daewoong Pharmaceutical is now conducting phase 3 clinical trials for Envlo on dogs with diabetes, with plans to submit a drug application to the Animal and Plant Quarantine Agency this year.